Skip to main content

Markets surge even as job growth slows

The markets surged to close sharply higher with the Dow jumping 220 points to 25,295 even as job growth slowed in December. Nasdaq climbed 58 points to 7136.


On the upside


Momenta Pharmaceuticals (Nasdaq: MNTA) reported positive data from a Phase 1 study of M281.


CRISPR Therapeutics (Nasdaq: CRSP) priced its pubic offering of 5 million common shares at the discounted price of $22.75 peshare.


Diplomat Pharmacy (NYSE: DPLO) appointed Jeff Park as interim chief executive officer and affirmed its 2017 guidance.


On the downside


Kala Pharmaceuticals (Nasdaq: KALA) reported mixed results from two Phase 3 trials of KPI-121 to treat dry eye disease.


Core-Mark Holding (Nasdaq: CORE) warned that 2017 earnings will fall far short of previous guidance.


Regenxbio (Nasdaq: RGNX) provided a year end update.


In the broad market, advancing issues outpaced decliners by a margin of more than 3 to 2 on the NYSE and by nearly 3 to 2 on Nasdaq. The broader S&P 500 climbed 19 points to 2,743. Bitcoin plummeted $188 to $16,681.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.